Clinical Digest: Recent Clinical Trials on Scabies
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Scabies. These trials are organized by their release dates for your convenience. (Last updated on: 2025-05-02)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that empowers you to read articles, write articles, get answers, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Scabies
| Clinical Trial | Contact(s) | Date | |
|---|---|---|---|
| 1 | Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open label prospective pharmacokinetic single arm study in Laos PDR. This study will be embedded within a cluster-randomized controlled trial of interventions to address childhood undernutrition (SUANHOAM Trial, ACTRN12620000520932) and involves a collaboration with the Murdoch Children’s Research Institute, … |
AMANDA GWEE; | 2025-04-01 |
| 2 | Comparison of Topical Permethrin 1 Day Verses 2 Day Application Versus Oral Ivermectin for Treatment of Scabies in Children Greater Than 6 Yrs of Age PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies is highly contagious,pruritic infestation of skin.Various treatment modalities have been used but search for ideal scabicide is ongoing.we wnt to coduct this study to compare the outcome of permethrin verses ivermectin in children for treatment of scabies .This randomized clinical trial will be done in children hospital lahore for 12 months.Sample size of 90 cases;30 in each group will be included through non probability consecutive sampling.Then patient will be randomly divided into 3 groups.In group A patient will be given 5% permethrin topical application to whole body single application. In Group B ,patients will be given topical permethrin for twice application 24 hrs appart ,In group C patients will be given Tablet Ivermectin single dose 200microgram/kg.Then patients will be examined after 2 weeks and 4 weeks for no of lesions and pruritis and cure will be labeled.All this information will be recorded on performa .Data will be entered and analysed by using SPSS version 26.Three groups will be compared for cure by using chi-square test.P value less than and equal to 0.05 will be considered as significant. |
SADAF WAZIR; | 2025-04-01 |
| 3 | A Randomized Trial to Assess The Safety, Pharmacokinetics, Acceptability, and Efficacy of Pediatric Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The EPIC-15 trial will evaluate the safety, pharmacokinetics, acceptability, and efficacy of pediatric ivermectin (CHILD-IVITAB) in scabies infected children weighing 5 to less than 15 kg. This trial will support future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15 kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of pediatric ivermectin therapy |
LORENZ VON SEIDLEIN; | 2025-02-25 |
| 4 | The Effect of Parents’ Health Literacy on Primary School Students’ Health Screening Results PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Health literacy (HL) is defined by the World Health Organization (WHO) as the achievement of a level of knowledge, personal skills, and confidence to take action to improve individual and community health by changing personal lifestyles and living conditions. Health literacy is described as a concept encompassing various skills that enhance individuals’ quality of life, such as accessing accurate health information, developing healthy living behaviours, utilizing healthcare services, and making health-related decisions. To improve the health literacy of society, it is essential first to identify and enhance the health literacy of families, … |
MERVE CAKAR; | 2024-10-24 |
| 5 | The Effect of Using Projector Kaleidoscope and Matching Card on Children’s Fear and Physiological Parameters in 3-6 Year Old Children Who Are Administered Inhaler Medication PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This research was planned as a randomized controlled experimental type to determine the effect of using a projector caleidoscope and matching card on children’s fear and physiological parameters in 3-6-year-old children who were administered inhaler medication. According to the power analysis performed for the sample size, the power of the sample was calculated with the G*Power 3.1 program in line with the literature. While the amount of Type I error was 0.05 and the power of the test was 0.95 (α= 0.05, 1-β= 0.95), … |
ATIYE KARAKUL; | 2023-10-13 |
| 6 | Clinical Trial to Evaluate Efficacy and Safety of Sulfadoxine/Pyrimethamine-Amodiaquine and Dihydroartemsinin-Piperaquine Plus Ivermectin Administered Monthly As Intermittent Preventive Treatment in School-aged Children in Burkina Faso PF:8 Related Papers Related Patents Related Grants Related Experts View Highlight: This will be an open label cluster randomized study with two active intervention and one control arm. A cluster will be defined as a selected village. One district implementing seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly selected in this district. These six villages will be randomly allocated to each of the three study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine (SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM), … |
JANE ACHAN; | 2023-07-15 |
| 7 | A Phase 2, Placebo-controlled, Double-blind, Randomized, Dose Ranging, Efficacy and Safety Study of Orally Administered Moxidectin in Adults With Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Moxidectin is not approved to treat scabies in humans. The effective dose of moxidectin to treat scabies is not known. This study aims to assess the efficacy of a single administration of 8 mg, 16 mg, or 32 mg moxidectin per oral in achieving Scabies Complete Cure at Day 28. This study also aims to assess the safety of three strengths of single moxidectin doses in adults with scabies. |
OSCAR DE VALLE; | 2023-06-25 |
| 8 | A Randomised, Double-blind, Placebo-controlled Trial to Assess The Safety, Pharmacokinetics, and Efficacy of Escalating Doses of Oral Ivermectin in Scabies Infected Children Weighing 5 to Less Than 15 Kilograms PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This trial will evaluate the safety, pharmacokinetics, and efficacy of ivermectin in scabies infected children weighing 5 to less than 15kg. This will allow future efforts to expand the indication of ivermectin treatment to infants weighing 5 to less than 15kg to treat numerous NTDs, allowing this young age group equitable access to the numerous benefits of ivermectin therapy. |
LORENZ VON SEIDLEIN; | 2023-03-01 |
| 9 | Comparison of Effectiveness Between Three Dosages of Oral Ivermectin, Two Dosages of Oral Ivermectin, and Two Applications of Topical Permethrin In Scabies Patients PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies is a skin disease characterized by intense itching that worsens at night. It is very contagious, still has a high occurrence rate, and impacts patient quality of life. The use of scabicide followed by a clean and healthy lifestyle is the principle of scabies therapy. The primary treatment option for scabies is permethrin 5% cream. Ivermectin is an alternate treatment for scabies. |
HENDRA GUNAWAN; | 2023-01-25 |
| 10 | Place of Hygiene in Scabies’s Treatment in Populations in Precarious Situations PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies is a parasitic pathology contracted mainly through human contamination. It is caused by a parasite (Sarcoptes Scabiei var. hominis) which lodges into the top layer of the epidermis creating a burrow, which can measure 5 mm to 15 mm, where the female lays her eggs. After 4-6 weeks the patient develops an allergic reaction to the presence of mite proteins and feces in the scabies burrow, causing intense itch and rash. The usual adult form, called common scabies, is characterized by this nocturnal pruritus, … |
BACHA KAOUTAR; | 2022-04-01 |
| 11 | Comparing Sulfur to Different Regimes of Permethrin for The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: In 2017, the World Health Organization (WHO) labeled scabies as a neglected tropical disease. It is a serious health problem especially in poor developing countries like Syria, where overcrowding, poverty, and war consequences are considered major factors for spreading the disease. Permethrin lotion or cream is the treatment of choice for scabies, and it is applied once a week for two consecutive weeks according to the global guidelines. However, most practitioners in Syria do not adhere to this standard regimen, and a variety of regimens are used instead based mostly on clinical experience. In this study, … |
DAMASCUS UNIVERSITY | 2022-03-15 |
| 12 | A Single Treatment Pharmacokinetic and Safety Study of Natroba (spinosad) Topical Suspension 0.9% W/w in Subjects 1 Month to 3 Years 11 Months of Age with An Active Scabies Infestation PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: A population of approximately 50 pediatric subjects will be enrolled to assess the PK of spinosad and benzyl alcohol for 3 hours following a single, full-body topical application (open label) on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be approximately 50 subjects ages 1 month to 3 years 11 months of age enrolled with the goal of completing approximately 16 subjects. With assistance from a caregiver, … |
WILLIAM MILLER; | 2022-03-04 |
| 13 | Comparison of Topical 5% Permethrin and Topical 10% Sulfur in The Treatment of Scabies PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Sarcoptes scabiei is responsible for a skin infection called scabies. Permethrin is most widely used anti-scabicidel drug and is taken as drug of choice because of its efficacy, safety and patient’s compliance. Sulfur 6-33%, as cream, ointment or lotion, is recommended by the European guidelines as an effective alternative treatment and is among the oldest treatments used for scabies. It is recommended to be applied for 3 consecutive days. Both permethrin and sulfur have been shown in previous studies to be superior to other anti-scabietic drugs in terms of efficacy. Two studies showed that permethrin was more efficacious than sulfur, … |
ALEENA NASIR; | 2022-03-01 |
| 14 | Streptococcus Pyogenes Carriage Acquisition, Persistence and Transmission Dynamics Within Households in The Gambia: A Longitudinal Cohort Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Group A Streptococcus (GAS) is a bacteria which causes severe infections and leads to deadly diseases such as rheumatic heart disease which kills over 300,000 people a year globally, particularly in low-income countries. It is not know how GAS is spread between people, how often people carry GAS in their throat or on their skin without having symptoms, or what factors increase the chance of this occurring. It is important to understand these factors in order to know how to reduce GAS-related disease. This study will follow 444 people in The Gambia, over 12 months, … |
EDWIN P ARMITAGE; | 2021-07-27 |
| 15 | Prospective, Open-label, Multicenter, Initially Single-armed and in Case of Treatment Failure Subsequently Three-armed Randomized Clinical Trial of Phase III/IV Investigating The Escalated Therapy of Scabies With INFECTOSCAB 5% (Permethrin) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The ETSKABI study is a prospective, open-label, multicenter, initially single-armed and in case of treatment failure subsequently three-armed randomized clinical trial. Within the initial treatment phase, the to-date clinical efficacy of the standard therapy regimen according to the current German S1-guideline for the diagnosis and treatment of scabies is to be examined. The subsequent second phase focusses on three differently escalated treatment regimens in order to evaluate their potential to cure those patients still suffering from Scabies after standard therapy. In total, … |
CORD SUNDERKÖTTER; | 2021-06-11 |
| 16 | Comparative Study Between Topical Permethrin 5% and Oral Ivermectin for The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Globally, Scabies infects 300m people each year. In children of developing countries, its prevalence is expected to be about 5 to 10%.In Pakistan, Scabies accounts for 38% of dermatological diseases. Males were more prone to infestation than females, and early school-aged children were the most vulnerable. It was more widespread in urban than in rural areas. A distinct seasonal pattern emerged, with the biggest infestation occurring in the winter and the lowest in the summer. Scabies risk factors estimated 89% of the variation in its prevalence. The classic scabies symptoms include an erythematous papular eruption, burrows, … |
NAHEED KHAN; | 2021-06-01 |
| 17 | Adjunctive Ivermectin Mass Drug Administration for Malaria Control on The Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a cluster-randomized placebo-controlled clinical trial to evaluate the additive benefit of Ivermectin (IVM) (or Placebo) mass drug administration (MDA) to dihydroartemisinin-piperaquine (DP) MDA for malaria control in a moderate to low malaria-endemic setting as an adjunctive strategy to existing programmatic malaria control measures. The regime of DP and IVM will target both human reservoirs of Plasmodium falciparum and the Anopheles gambiae vector respectively, with the aim of interrupting transmission. The trial will be conducted on the Bijagos Archipelago, … |
ANNA R LAST; | 2021-05-03 |
| 18 | Risk Factors for Treatment Failure of Scabies in Autochthonous Populations of French Guiana (GUYAGALE) PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies is a Neglected Tropical Disease, particularly important in autochthonous populations. Treatment failures could explain the high prevalence of this disease in Amerindian and Maroon populations of French Guiana. Our main objective is to look for specific sociodemographic risk factors for treatment failure of scabies in the remote areas of French Guiana. A secondary objective is to evaluate the prevalence of scabies and its complications. |
ROMAIN BLAIZOT; | 2021-03-29 |
| 19 | High-Dose Ivermectin for Mild-to-Moderate COVID-19 – The (HD)IVACOV Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for COVID-19. Although ivermectin demonstrated potent in vitro action by reducing viral load by 5000x after 48 hours of incubation, simultaneous pharmacokinetics simulations suggested that the minimum effective concentrations would be unfeasible to be reached within safety range (EC-50 = 2 Micromol). However, despite the theoretical unfeasible concentrations to be achieved, preliminary observational yet well-structured studies followed by randomized clinical trials (RCTs) demonstrated ivermectin efficacy when combined with hydroxychloroquine, … |
FLAVIO A CADEGIANI; | 2021-01-25 |
| 20 | Contagious Itch, Disgust and Empathy in Patients and Medical Staff PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study is to assess the relationship between CI, disgust and empathy in medical staff treating patients with scabies, to differentiate the impact of visual and verbal stimuli contributing to CI and to assess information about CI, disgust and empathy in a family infested with scabies. |
SIMON MUELLER; | 2020-09-16 |
| 21 | Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess The Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: This study aims to evaluate the efficacy, safety and tolerability of Ivermectin in patients with mild SARS-CoV-2 infection, in the rate of progression to severe 2019 novel coronavirus disease (COVID-19). The primary efficacy endpoint is the proportion of participants with a disease control status defined as no progression of severe disease Hypothesis (H0): There is no difference between group A (ivermectin + paracetamol) and group B (ivermectin + paracetamol) in terms of the primary endpoint on day 14. |
ALMA M PEREZ; | 2020-07-01 |
| 22 | Evaluation of Ivermectin, Aspirin, Dexamethasone and Enoxaparin As Treatment of Covid19 PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: The associated use of Ivermectin, aspirin, dexamethasone, and enoxaparin (in different combinations and doses) will reduce the impact of COVID infection 19, the need of admission to the intensive care unit, and mortality. |
HECTOR E CARVALLO; | 2020-05-01 |
| 23 | A Phase II, Randomized, Double-blind, Parallel Group Dose Finding Study of Single Oral Doses of Moxidectin in Adults With Scabies PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The effective dose of moxidectin to treat human scabies is not known. This study aims to provide proof of concept that a single dose of moxidectin is effective in eliminating the scabies parasite in humans and to enable the determination of an optimal dose of moxidectin for treatment of scabies for further clinical studies. |
MEDICINES DEVELOPMENT FOR GLOBAL HEALTH | 2020-01-13 |
| 24 | School-based Interventions to Promote Personal and Environmental Hygiene Among Children in Pakistan: Protocol for A Mixed Methods Study PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Poor personal hygiene and inadequate sanitation practices among young children in Low Middle Income Countries such as Pakistan can lead to critical, life-threatening illnesses such as respiratory infections, diarrheal disease, malnutrition and developmental delays. An intervention for personal/environmental hygiene practices for primary schoolchildren will be implemented at schools in urban squatter settlements of Karachi, Pakistan, aiming to improve the hygiene knowledge and practices (K&P) amongst primary schoolchildren and their mothers (participants), … |
NOUSHEEN PRADHAN; | 2018-12-21 |
| 25 | A Randomized Controlled Trial Comparing The Effectiveness of Individual Vs. Household Treatment for Scabies in Lambaréné, Gabon PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: It is unclear whether individual treatment of scabies is similarly effective compared to household treatment. This study therefore compares these two treatment strategies with topical benzyl benzoate for treating scabies in Lambaréné and surroundings in Gabon. Subjects presenting with uncomplicated scabies are randomized into either the Individual Treatment group, where only the affected subjects receive treatment, or the Household Treatment group, where all family members are treated in parallel to the affected subjects regardless of signs and symptoms. The primary endpoint is clinical cure after 28 days; … |
JULIAN MATTHEWMAN; | 2018-10-04 |
| 26 | A Cluster Randomised Trial of The Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases PF:9 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a cluster randomised trial evaluating the safety of co-administering Azithromycin alongside the new IDA (Ivermectin, Diethylcarbamazine, Albendazole) combination treatment for LF. Treatment will be provided as a single dose Mass Drug Administration (MDA) to the whole community. Communities will be randomised to receive either treatment with IDA and Azithromycin on the same day or separately. Active monitoring for adverse events will be conducted and the frequency of adverse events compared between individuals receiving combined MDA or separate MDA. |
ORIOL MITJA; | 2018-10-01 |
| 27 | Efficacy and Side Effects of Blacksoap® As Adjuvant Therapy of Scabies: A Single-blind Randomized Control Trial PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: Background: Scabies is a skin disease due to Sarcoptes scabiei. The transmission risk is high among communities living together, such as dormitories, boarding schools, nursing homes, and so on. Blacksoap® is a soap product that is recognized as adjuvant therapy. Until now, there has been no research on the effectiveness and side effects of using Blacksoap®. Purpose: This research aimed to assess the cure rate of standard scabies treatment, with and without Blacksoap®, to determine pruritus visual analog scale (VAS) score, transepidermal water loss (TEWL) score before and after receiving therapy, … |
SANDRA WIDATY; | 2018-09-18 |
| 28 | A Double Blind, Two Arm, Multicenter, Randomized, Parallel Group, Bioequivalence Study With Clinical Endpoints to Evaluate The Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application. |
SAPTALIS PHARMACEUTICALS | 2018-04-10 |
| 29 | A Randomized Controlled Double-blind Trial Assessing The Efficacy of A 400µg/kg Ivermectin /5% Permethrin / Emollient Cream Regimen in Patients With Crusted Scabies As Compared to A 200µg/kg Ivermectin /5% Permethrin /Emollient Cream Regimen PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Severe forms of scabies (crusted scabies and profuse scabies) require a specific treatment. Ivermectin is a recommended treatment in common forms of scabies and represents a promising treatment in crusted scabies in case reports. However, response to ivermectin remains variable among studies, and there is no consensus on the schemes to adopt (dosages and administrations). Ivermectin at 400 µg/kg has already been used, without showing toxicity (in head lice treatment in particular). Investigators propose to demonstrate that 400µg/kg ivermectin dosage will show better efficacy than a 200µg/kg in patients with severe forms of scabies (crusted and profuse). |
GIAO DO-PHAM; | 2017-10-11 |
| 30 | Impact of Community Scabies Treatment on Head Lice Prevalence in The Solomon Islands PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a pilot study evaluating if treatment for scabies also treats headlice in the same community |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE | 2017-08-01 |
| 31 | Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji. There is a dedicated LF eradication program supported by the World Health Organization (WHO), however scabies and STH are currently managed on an individual level with symptomatic treatment as required. In an attempt to reduce the prevalence of LF globally, research is being undertaken into alternative, more effective treatment options. A recent study in Papua New Guinea demonstrated a new triple drug therapy (ivermectin, … |
ANDREW STEER; | 2017-07-13 |
| 32 | A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate The Therapeutic Equivalence of Permethrin Cream, 5% (Encube Ethicals) Compared to Elimite™ Cream (Permethrin) 5% (Prestium Pharma, Inc.) in The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5%in the Treatment of Scabies. |
ENCUBE ETHICALS PVT | 2017-06-01 |
| 33 | A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess The Safety and Efficacy of Natroba™ (Spinosad) for The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the complete cure of scabies after a single treatment. |
PARAPRO | 2017-05-10 |
| 34 | A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess The Safety, Efficacy and Pharmacokinetics of Natroba™ (Spinosad) for The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the clinical cure of scabies after a single treatment. The trial will also assess the pharmacokinetics (PK) of spinosad and benzyl alcohol following a single dose of Natroba™ in pediatric subjects 4-16 years of age. These subjects will be a separate population of pediatric subjects. |
PARAPRO | 2017-05-02 |
| 35 | Better Disease Control By Multidrug Regimen in Scabies: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies is associated with significant discomfort and social taboo. Existing treatment regimen frequently fails due to lack of patient compliance. We compared single use regimen to existing standard repeat application regimen for treatment of scabies. |
PRAJWAL PANDEY; | 2017-01-01 |
| 36 | A Multi-center, Double-blind, Randomized, Parallel-group Study Comparing Permethrin Cream, 5% With Elimite™ in Patients With Active Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: This is a multi-center, double-blind, randomized, two arm parallel design study. This study is comprised of two phases: screening and treatment. The screening period will be up to 5 days, followed by the treatment phase of 28±4 days. During the treatment phase subjects will be randomized to receive either test or reference treatments in a double-blind manner in an outpatient setting. Randomization of subjects will be in a 1:1 ratio for the test and reference drug arms and will be stratified by site. Screening will begin at visit 1, … |
MAYNE PHARMA INTERNATIONAL PTY | 2016-11-01 |
| 37 | Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies – Impact on Impetigo and Skin Microbiology PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: This is an open-label prospective community intervention trial to assess the impact of community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws bacterial skin infections. Communities will be randomised to receive standard treatment for both yaws and scabies either in parallel (site 1) or in sequence (site 2). Treatment of yaws: Single dose of Azithromycin (30mg/kg, max 2G). Treatment of scabies: Either an oral dose of Ivermectin (200μg/kg) or permethrin cream for those with a contraindication to Ivermectin (WT<15kg, ... |
MICHAEL MARKS; | 2016-07-01 |
| 38 | Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children: A Cluster Multicenter Randomized Trial PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies remains a frequent condition that affects adults and children. The aim of this study is to compare the efficacy and safety of two drug treatments against scabies in children and their close contacts. One group will apply topical permethrin 5% and the other group will receive oral ivermectin. Both groups will be treated twice, once at inclusion and the second time 10 days later. Both treatment regimens have been used widely and are safe to use. |
UNIVERSITY HOSPITAL BORDEAUX | 2016-01-01 |
| 39 | A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate The Therapeutic Equivalence of Permethrin Cream, 5% to Elimite™ Cream 5% in The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Scabies is an infestation of the skin by the human itch mite (Sarcoptes scabiei). Diagnosis of scabies is made based on clinical symptoms, such as nocturnal itching, and appearance and distribution of the rash. Definitive diagnosis includes the microscopic identification of the mite, mite eggs, … |
DR REDDY’S LABORATORIES | 2015-09-01 |
| 40 | A 60-Day Clinical Study to Evaluate Nutrilite Ginko Biloba Cistanche Tablets in Relieving The Symptoms of Chronic Fatigue Syndromes Compared to Negative Control PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: To evaluate the efficacy of Nutrilite® ginkgo biloba cistanche tablets in relieving the symptoms of chronic fatigue syndrome(CFS), the investigators randomly recruit189 subjects with CFS, aged 35-60 yrs. The relief of fatigue and improvement of sexual function are evaluated by World Health Organization Quality Of Life Brief (WHOQoL-Bref), Sexual Life Quality Questionnaire (SLQQ), chronic fatigue syndrome, symptoms of self-assessment at the baseline and the end of intervention. Subjects also underwent a blood test measuring the concentration of biochemical indicators. Cistanche is mainly used to strengthen the renal function, nourish essence and blood in the treatment of lumbar debility, impotence, … |
SHUGUANG LI; | 2015-05-01 |
| 41 | PCR (Polymerase Chain Reaction) Assay for Diagnosis of Sarcoptes Scabiei PF:2 Related Papers Related Patents Related Grants Related Experts View Highlight: The main objective of this study is to identify unique DNA sequences within the genome of human scabies that can be utilized to identify the parasite through PCR. |
DAYNA DIVEN; | 2014-10-01 |
| 42 | Veron Scabies Education and Eradication Program PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this project is to develop a community scabies eradication and education program for the highly endemic areas surrounding the Veron community on the eastern tip of the Dominican Republic. It proposes the use of oral Ivermectin as a replacement for topical Lindane–a readily available medical formulation, pesticide, and environmental toxin that is reported to be banned in the Dominican Republic as well as over 80 other countries throughout the world. |
JEREMY J WHITE; | 2007-05-01 |
| 43 | The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) – Part 4 -The Prevalence of Group A Streptococcal Pyoderma and Scabies in Infants in Fiji PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: Group A streptococcus (GAS) is a bacteria that causes many different sicknesses in children and adults. This study will look at the number of cases of pyoderma (bacterial skin infection) and scabies (skin mites that cause itching) in 550 infants 12 months or younger in Fiji. (GAS can cause pyoderma, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2007-02-01 |
| 44 | The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 1: The Prevalence of Rheumatic Heart Disease, Pyoderma and Scabies in School Children in Fiji PF:7 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to estimate the number of cases of rheumatic heart disease, pyoderma, and scabies in school age children in Fiji. In addition the study will describe the features of rheumatic heart disease, pyoderma, and scabies in these children. Study participants will include 5200 primary school children, ages 5-14, from 21 primary schools in the Central Division of Fiji. These children will be examined for pyoderma, scabies, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2006-01-01 |
| 45 | The Epidemiology of Group A Streptococcal Infections in Fiji (Fiji GrASP) Part 3: The Incidence of Group A Streptococcal Pharyngitis and The Prevalence of Pyoderma and Scabies in School Children in Fiji, and Establishing Immunologic Correlates of Protection for A J8 Vaccine PF:5 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to find out how often group A Streptococcus (GAS) occurs in school-age children of Central Fiji. This bacterium often causes pharyngitis (sore throat) and can also cause pyoderma (skin infection) or scabies. Approximately 1000 children ages 5-14 years will be enrolled from 4 primary schools in Central Fiji. These children will have throat swabs performed to determine how commonly GAS occurs. Over the next 10 months, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2006-01-01 |
| 46 | Efficacy and Nutritional Assessment Following Albendazole and Combined Albendazole/Ivermectin Treatment for Intestinal Helminth Infections in Rural Guatemalan Schoolchildren PF:4 Related Papers Related Patents Related Grants Related Experts View Highlight: The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, … |
MICHAEL J BEACH; | 2005-02-01 |
| 47 | East Arnhem Healthy Skin Project: A Regional Collaboration to Reduce Scabies, Skin Sores and Associated Chronic Diseases, Including Rheumatic Fever and Renal Disease, Among Australian Aboriginal Communities PF:6 Related Papers Related Patents Related Grants Related Experts View Highlight: The purpose of this study is to determine whether a coordinated regional approach to healthy skin programs in six remote Aboriginal communities can demonstrate, not only a reduction in the burden of scabies and streptococcal skin sores, but also broad health benefits, including primary prevention of some chronic diseases that occur at particularly high rates in Australian Aboriginal communities. The primary objectives of the Program are: – Demonstrate a reduction in scabies and skin sores on a regional basis – Demonstrate the broader public health effects of Healthy Skin Programs, … |
ROSS M ANDREWS; | 2004-09-01 |
| 48 | A Randomised, Double Blind, Double Dummy Study to Compare The Efficacy and Safety of A Single Administration of Ivermectin to A Single Administration of Permethrin for The Treatment of Scabies PF:3 Related Papers Related Patents Related Grants Related Experts View Highlight: Comparison of the efficacy and safety of a single administration of ivermectin to a single administration of permethrin for the treatment of scabies |
JEAN-MARIE NAEYAERT; | 2004-07-01 |